Table 1 Demographics and baseline disease characteristics of the biomarker population by treatment arm
Biomarker population | ||
|---|---|---|
Baseline parameter | Adalimumab 40 mg q2w (n = 152) | Sarilumab 200 mg q2w (n = 148) |
Age, years, mean (± SD) | 53.3 (± 12.0) | 50.4 (± 12.5) |
Female, n (%) | 121 (78.6) | 128 (83.7) |
Caucasian, n (%) | 135 (87.7) | 141 (92.2) |
Duration of RA, years, mean (± SD) | 6.6 (± 8.1) | 7.9 (± 8.1) |
Swollen joint count, mean (± SD) | 17.26 (± 10.1) | 18.5 (± 10.6) |
Tender joint count, mean (± SD) | 26.9 (± 13.9) | 28.1 (± 13.4) |
IL-6, pg/mL, median [Q1–Q3] | 19.79 [5.86–54.59] | 14.40 [4.55–47.02] |
IL-6 tertile†, n (%) | ||
Low | 45 (29.6) | 55 (37.2) |
Medium | 53 (34.9) | 47 (31.8) |
High | 54 (35.5) | 46 (31.1) |